Treatment of Medial and Lateral Elbow Tendinosis with an Injectable Amniotic Membrane Allograft – A Retrospective Case Series

Danielle Aufiero1,*, Steven Sampson2, Kentaro Onishi3 and Angie Botto-van Bemden4

1The Orthohealing Center, Los Angeles, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA. 2Western University of Health Sciences, Pomona CA; Touro University California, Vallejo, CA. 3The Orthohealing Center and The Orthobiologic Institute (TOBI), David Geffen School of Medicine at University of California Los Angeles, CA; 10780 Santa Monica Blvd, Suite 440, Los Angeles, CA 90025 Western University of Health Sciences, Pomona CA; Touro University California and Touro University New York; NY. 4Musculoskeletal Research International (MRI) and Clinical Research Experts (CRE) Fort Lauderdale, FL; Florida International University, Miami.

Abstract

Background: Epicondylitis is the second most frequently encountered head and upper limb musculoskeletal diagnosis in primary care clinics, with an incidence rate as high as 7/1,000 patients per year. Chronic or recalcitrant epicondylitis- more appropriately termed epicondylosis or elbow tendinosis- is not uncommon and represents a notable set of pathologies which account for lost recreation time, decreased quality of life, and workers compensation claims. A novel non-operative option has recently become available in the form of micrized dehydrated human amniotic/chorionic membrane (mDHACM) allograft.

Hypothesis: mDHACM allograft is known to be rich in anti-inflammatory cytokines and tissue inhibitors of metalloproteinase and IL-10. It also contains an abundance of growth factors and cytokines. In vivo and in vitro studies have shown reduction in scar tissue. We hypothesize that mDHACM allograft will be a viable treatment option in patients with epicondylitis.

Study design: Retrospective case series.

Level of evidence: IV

Methods: Charts were retrospectively reviewed for 10 patients who received mDHACM allograft injections for treatment of medial or lateral epicondylitis.

Keywords: Micrized dehydrated human amniotic/chorionic membrane (Mdhacm) allograft; Elbow tendinosis; Orthobiologics; Injectable amniotic membrane; Elbow epicondylitis

Introduction

Epicondylitis is the second most frequently encountered head and upper limb musculoskeletal diagnosis in primary care clinics, with an incidence rate as high as 7/1,000 patients per year [1,2]. It is believed to be a degenerative process, elicited from repetitive microtrauma and failure of the innate healing response based on biopsies from affected tissue having demonstrated angiofibroblastic hyperplasia, void of inflammatory markers. Activities requiring repeated contraction of the wrist extensors are implicated, with the extensor carpi radialis brevis (ECRB) tendon most commonly involved. Traditional non-operative treatment options for epicondylitis include physical therapy, bracing, topical or oral anti-inflammatory medication, and corticosteroid injections [3-7]. Prior publications reporting the pathophysiology of tendinosis being an angiofibroblastic and mucoid degenerative process rather than an inflammatory one argues against the use of corticosteroid injection since its anti-inflammatory property will not alter such degenerative tissue changes [8,9]. Additionally, corticosteroid injections are considered toxic to tenocytes and may be deleterious to the tissue as therapeutic agents; including, platelet-rich plasma (PRP), autologous blood injection (ABI), bone marrow aspirate concentrate (BMAC), and adipose-derived cell therapies.

The most common researched RIT for tendinopathy is PRP, for which several studies have suggested its efficacy in lateral epicondylitis [14-18]. PRP provides a rich cocktail of pro-inflammatory and anti-inflammatory cytokines representing a non-specific milieu of growth factors. PRP preparation has not been standardized and great variability exists from patient to patient which may affect outcomes. Future treatments are aimed at providing a more customized approach by isolating particular cytokines, such as interleukin-1 (IL-1) receptor antagonist and tumor necrotic factor-alpha antagonist (TNF-alpha), in an attempt to arrest degenerative processes contributing to tendinosis.


© 2016 Aufiero et al., This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
of micronized dehydrated human amniotic/chorionic membrane (mDHACM) allograft derived from the basement membrane of healthy placenta donated from cesarean procedures. Amniotic membrane tissue is non-immunogenic with very little to no expression of human leukocyte antigens (HLAs), and hence does not elicit a substantial host rejection response [19-23]. Similar to current RITs, the mechanism of action remains to be elucidated; yet, mDHACM is known to be rich in anti-inflammatory cytokines such as interleukin (IL)-1 and IL-2 receptor antagonist; and tissue inhibitors of metalloproteinase (TIMP) -1, -2, -3, -4, and IL-10. It also contains an abundance of growth factors and cytokines including epithelial growth factor (EGF), transforming growth factor beta (TGF-beta), basic fibroblastic growth factor (bFGF), and platelet derived growth factor alpha and beta (PDGF a and b), all of which are vital to the three phases of tendon healing (inflammatory, proliferative, and remodeling [24]. In vivo and in vitro studies have shown reduction in scar tissue and inflammation [23,25-27]. Prior publications have documented its safety and efficacy in various applications including chronic wound healing, chronic ocular surface lesions, plantar fasciitis, dentistry and spinal surgeries [23,25,28-30]. The purpose of this manuscript is to present a retrospective case series of ten patients treated with an injection of mDHACM allograft for either medial or lateral epicondylosis refractory to conventional treatments.

Materials

Micronized dehydrated human amniotic/chorionic membrane (mDHACM) allograft (AmmioFix Injectable, MiMedx Group Inc, Marietta GA) reconstituted with 0.5 cc sterile water was used to treat all patients. This amnion/chorion configuration presents as a powder that can be mixed with sterile saline to create a liquid (micro-grafts are suspended in the saline) for injection into or adjacent to the targeted damaged soft tissue.

Methods

The Western Institutional Review Board (WIRB) noted that this case series met the conditions for exemption under 45 CRF 46.101(b) (4). All of the data was in existence and the information was recorded in such a manner that subjects could not be identified, directly or through identifiers linked to subjects. Importantly, our standard protocol with all patients presenting to our clinic includes review of all available treatment options and careful selection of best treatment option for each individual patient- all patients consented to treatment.

Chart review

A retrospective chart review was performed on all patients injected from 2012-2013 with mDHACM allograft for treatment of epicondylosis- ten patients in total. It is standard protocol at our clinic for all patients to complete the various gold standard patient reported outcome (PRO) scales for their particular musculoskeletal condition. Thus, this epicondylosis patients completed a Visual Analogue Scale (VAS) for pain (ranging from 2/10-8/10 with average of 5.2) as well as the Quick Disability for Arms, Shoulders and Hands (Quick DASH) score to assess functional improvement during their office visits. Patients underwent a physical exam as well as a musculoskeletal ultrasound (MSK US) of the affected region prior to injection. Patient follow-up visits included 6-8 weeks, 12-16 weeks and 24-36 weeks post-injection.

History

All patients had recalcitrant symptoms of epicondylosis for at least three months, failing physical therapy and at least two other traditional treatment options (ie bracing, compounding cream, NSAID’s, cortisone injection). Four of the patients also had failed alternative treatments including acupuncture, PRP and prolotherapy. No patient had received a PRP or prolotherapy injection less than six months prior or corticosteroid injection less than two months prior to mDHACM allograft injection. None of the patients had concurrent cervical radiculopathy or any other upper extremity condition confounding their pain when offered mDHACM allograft injection treatment. No patients had history of surgical repair of the affected tendon. Patient baseline characteristics are provided in Table 1.

Physical exam

All patients had tenderness about the affected epicondyle and the presence of pain with resisted extension or flexion for lateral or medial epicondylosis, respectively. Additionally, all patients expressed pain or discomfort with passive stretching of the affected tendon.

Musculoskeletal ultrasound

All enrolled patient's revealed evidence of mild/moderate tendinosis at either the medial or lateral epicondyle, characterized by at least two of the following ultrasound findings: loss of normal fibrillar pattern (Figure 1), areas of hypoechoic signal changes within the tendon (Figure 2), or significant thickening of the tendon (Figure 3). None of the ultrasound images revealed high grade tears.

mDHACM allograft injection

Upon procedural consent, the target region was prepped and local anesthetic consisting of 1% lidocaine was injected subcutaneously via 25 gauge 1 ¼ inch needle. The product arrives from the company and the package is opened while dropping the bottle onto a sterile field. Using sterile gloves, 0.5 cc of sterile water was added to the vial to reconstitute the injectable via a 3cc syringe and 18G needle. The needle is switched from 18 gauge drawing needle to 22 gauge 1 1/2’’ capped injection needle, and is ready for the doctor to inject. Patients then received MSK US-guided injection of 40mg mDHACM allograft reconstituted with 0.5 cc sterile water to the affected epicondyle at the maximum tender point, which was typically the tendon-osseous junction. If a specific region of hypoechoic change located was consistent with micro-tearing, this region was targeted and the mDHACM allograft would “fill” the hypoechoic gap (Figure 4). When the tendon was more diffusely thickened with loss of normal fibrillatory pattern, mDHACM allograft was injected into the tendon’s superior aspect to visualize spread along the tendon sheath (Figure 5). Icing was performed immediately after the procedure for a total of five to ten minutes with subsequent application of an ACE wrap.

Patients were cleared to use anti-inflammatory medication (over the counter or prescribed) and told to ice as needed for 20 minutes per session up to five times per day. Finally, patients were instructed to avoid any aggravating activity for at least five days and to ease back into their normal activity as tolerated.

Data analysis

Minitab 17 Statistical Software (State College, Pennsylvania) was used for statistical analysis. Significance was set at <0.05 and the 95% confidence interval were used. ANOVA analyses were performed for VAS, Quick DASH and Subject Rated Percentage Improvement of Pain upon confirming normality and constant variance assumptions. The average percentage improvement for the population can either be negative or positive, indicating that the patients can either get better or worse; the change would thus not be statistically significant (p>0.05). Based on our results, the 95% confidence intervals at weeks 6-8, 12-16, and 24-36 are all positive intervals, indicating that at each time point the mean patient percentage improvement for the population is positive (the patients are doing better), and the improvement is statistically significant (p<0.05). It also should be noted that the 95% confidence intervals increased with time, which also demonstrates that the patients...
Table 1: Patient baseline characteristics.

<table>
<thead>
<tr>
<th>PT</th>
<th>M/F</th>
<th>Dominant/NonME/LE</th>
<th>Activity causing pain</th>
<th>Therapies tried previously</th>
<th>PreVAS Post-VAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>Non-Dominant LE</td>
<td>Playing drums</td>
<td>P, C, B, Ac, AM</td>
<td>8/10</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>Non-Dominant ME</td>
<td>Tennis</td>
<td>P, C, PRP, B, AM</td>
<td>6/10</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>Dominant LE</td>
<td>Weight lifting</td>
<td>P, C, AI, B, AM</td>
<td>4/10</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>Non-Dominant LE</td>
<td>Weight lifting</td>
<td>P, C, PRP, B, AM, Pro</td>
<td>4/10</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>Dominant LE</td>
<td>Sailing</td>
<td>P, AI, AM</td>
<td>6/10</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>Dominant ME</td>
<td>Tennis</td>
<td>P, B, AM</td>
<td>4/10</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>Dominant ME</td>
<td>Weight lifting</td>
<td>P, C, B, AM</td>
<td>6/10</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>Dominant ME</td>
<td>Tennis</td>
<td>P, AI, B, AM, Pro</td>
<td>2/10</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>Dominant ME</td>
<td>Opening doors</td>
<td>P, AI, B, AM, Pro</td>
<td>8/10</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>Dominant LE</td>
<td>Opening doors</td>
<td>P, C, B</td>
<td>8/10</td>
</tr>
</tbody>
</table>

P: Physical Therapy; C: Corticosteroid; PRP: Platelet-rich plasma; AI: Anti-inflammatory medications (oral/topical); B: Bracing; Ac: Acupuncture; AM: Activity Modification; Pro: Prolotherapy.

Results

Safety

No significant adverse event was reported during the study. Most common expected adverse reaction was soreness at injection site (n=8) with one patient having prolonged soreness up to two weeks.

Visual analogue scale for pain (VAS)

At the initial evaluation, patients reported a baseline pain level ranging from 0-10 with 10 signifying the worst pain imaginable. Baseline mean VAS was 5.20 and at 24-36 weeks follow-up mean VAS was 2.06. The mean VAS difference between baseline and final follow-up at 24-36 weeks was 3.14 with a p value < 0.0003.

Quick disability for arms, shoulders, and hands (Quick DASH)

At the initial evaluation, patients were asked to complete Quick DASH questionnaire. Baseline means Quick DASH score was 27.73 and at 24-36 weeks follow-up the mean Quick DASH score was 7.10. The mean Quick DASH score difference between baseline and final follow-up at 24-36 weeks was 20.62 with a p value < 0.0000.

Subject rated percentage improvement of pain

Patients reported their percentage of pain improvement from baseline at each follow-up visit. At final follow-up of 24-36 weeks patient percentage improvement of pain was 77% with a p value < 0.0001. Mean values at each time point along with the standard error of the mean pooled estimates (SEMp) are provided in (Table 2).

Discussion

Traditionally, the non-operative treatments for elbow tendinosis have been physical therapy, bracing and/or corticosteroid injection to the painful epicondyle [13]. Orthobiologics are increasingly used more often instead of corticosteroids for musculoskeletal indications and most recently, non-operative practitioners are employing the use of RIT. Since orthobiologics like PRP, BMC, etc. are patient dependent as well as technique dependent; there is much variability within the ultimate orthobiologic product derived from each patient's blood. In contrast, mDHACM allograft is derived from the placenta membrane in a reproducible fashion, offering predictable concentration and
Table 2: Mean subject rated percentage improvement of pain by time vs zero.

<table>
<thead>
<tr>
<th>Time</th>
<th>n</th>
<th>Mean</th>
<th>SEMp</th>
<th>LowerCL</th>
<th>UpperCL</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>10</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>6-8 weeks</td>
<td>10</td>
<td>0.46</td>
<td>0.09</td>
<td>0.28</td>
<td>0.64</td>
<td>0.0001</td>
</tr>
<tr>
<td>12-16 weeks</td>
<td>10</td>
<td>0.57</td>
<td>0.09</td>
<td>0.38</td>
<td>0.75</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>24-36 weeks</td>
<td>10</td>
<td>0.77</td>
<td>0.09</td>
<td>0.58</td>
<td>0.95</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

absolute value ranges for its specific growth factor and cytokine panel. mDHACM allograft processing combines cleaning and sterilization of the amniotic, plantar fascia. This is a degenerative tissue condition rather than inflammation. They compared 1.25 cc saline (control) injections, to either 0.5 cc mDHACM allograft injections, or 1.25 cc mDHACM allograft injection - 45 patients were randomized to one of the three groups, with 15 patients in each. Patients were followed for 8 weeks in regards to pain and function. They reported significant improvements in both treatment groups compared to control the group at 1 week post injection and throughout the study period. Week 1 American Orthopaedic Foot and Ankle Society (AOFAS) Hindfoot scores increased by a mean of 2.2 ± 1.74 points for controls versus 38.7 ± 11.4 points for those receiving 0.5 cc mDHACM (P < 0.001) and 33.7 ± 14.0 points for those receiving 1.25 cc mDHACM (P < 0.001). Week 8 AOFAS Hindfoot scores increased by a mean of 12.9 ± 16.9 points for controls versus 51.6 ± 10.1 and 53.3 ± 9.4 for those receiving 0.5 cc and 1.25 cc mDHACM, respectively (both P < 0.001). They found no significant difference in the treatment response between patients receiving 0.5cc versus 1.25cc of mDHACM allograft. They concluded mDHACM allograft injection as a viable treatment option in patients with refractory plantar fasciitis, noting larger studies are needed to confirm their results.

Philip and Hackl et al. [22] studied the Achilles tendons of rats by transecting, exposing and then treating them with either normal saline, amion-derived cell cytokine solution, or amnion membrane allograft. All tendons underwent mechanical stress testing. The authors concluded that amnion membrane allograft treated tendons exhibited a statistically significant increase in yield strength as well as Young modulus (a measurement of tendon stiffness) when compared with the saline treated control at 4 weeks but not at the earlier time points of 1 week or 2 weeks. This is contrary to the aforementioned findings in the human plantar fasciitis tendons where a significant difference was observed at 1 week post-injection and remained throughout the study. Unfortunately, our first follow-up time point did not occur until 6-8 weeks post-injection; thus, we cannot make a statement regarding treatment effects at earlier time points. Our data did reveal a statistically significant difference beginning at the first follow-up time point of 6-8 weeks until the final follow-up time point at 24-36 weeks.

Limitations

The present study is a small retrospective case series with many prior treatment variables subsequent to the nature of this recalcitrant group. Properly powered, prospective, double-blind randomized controlled trials are warranted, accounting for any confounding variables in the analyses. Future investigations on mDHACM allograft may also analyze parameters such as time of onset for noticeable symptom relief, duration of symptom improvement followed at least to 12 months post-procedure and if more than one injection is required at a certain time point. Future studies should include different tendon-beds to expand the knowledge behind this novel RIT.

Conclusions

mDHACM allograft demonstrated statistically significant improvements in epicondylitis when compared to baseline and this difference was clinically meaningful for our patients. mDHACM allograft may be a safe and viable treatment option in patients with elbow tendinosis.

References